Delivering quality therapy through generations
Search
 
  • Magyar
  • Русский
  • GR worldwide:
Skip Navigation Links
Printable version
 
Gedeon Richter is strongly interested in the licence-in of original, semi-original (value-added generic) or generic products 
Research Partnerships 
The costs of original pharmaceutical research and development – especially the expenses related to clinical trials – have spiralled globally over the past decade. Although the precise figures can vary greatly, it is a generally accepted rule of thumb that, today, the full development and market launch of a successful molecule entails an investment of approximately USD 100 million. If we factor in the development costs of compounds that never make it to the final stages of production, then this figure exceeds USD 500 million. Although these funds are spent over the course of an approximately ten-year period, the company is clearly unable to single-handedly bear the full cost of the development and global market launch of a new molecule.For this reason, one of our key objectives is to seek out industry partners with a view to forging research and development partnerships.

 

For this purpose, for more than two decades we have maintained excellent relationships with a number of Japanese pharmaceutical companies, such as Takeda Pharmaceuticals Company Limited, which is Japan’s leading pharmaceuticals manufacturer. Besides the Japanese connection, since 2000 the company has been making inroads to the USA, which today is the largest pharmaceuticals market, and home to the leading companies engaged in original research. We currently maintain R&D partnerships with two companies:

At the end of 2004, and in November 2005, we signed a total of three research agreements with US-based Forest Laboratories, which, although regarded as a mid-sized company in terms of its sales revenue, has an outstanding track record with respect to the clinical development and US distribution of compounds that act on the central nervous system. Within the framework of this partnership we are jointly continuing the clinical development of our RGH-896 (Radiprodil) pain-reliever, the RGH-188 (Cariprazine) antipsychotic.

Also in 2004, we signed a cooperation agreement with the Japanese Mitsubishi Pharmaceuticals corporation, regarding the joint development of Cariprazine.

We plan to sign additional cooperation agreements in the future, and to this end we are continuously examining opportunities for forming partnerships with European, American and Japanese partners. 

Name of compound

Clinical phase

Indications

Partner

Cariprazine (RGH-188)

F3

United States

Schizophrenia,

Forest Laboratories
F3

Japan

Bipolar Mania

Mitsubishi-Tanabe

F2

United States

Bipolar Depression Forest Laboratories
F2

United States

Major Depression Forest Laboratories

Radiprodil (RGH-896)

F2

United States

Chronic pain

Forest Laboratories

Licence-in

PRICE BOX
BSE 2010.07.29. 15:58
45 600 HUF - 2.13%